Posted in Clinical Data ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose April 1, 2026 Pharmaceutical Technology At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF. Clinical DataCardiovascularRead full story